Fig. 6.

A: representative raw tracing of raw and integrated CSN recordings before and after administration of endothelin-1 (ET-1). ET-1 infusion begins at first vertical dashed line and ends 10 min later at second dashed line. B: administration of the NMDA receptor blocker MK-801 substantially reduces the CSN response to ET-1 administration in CIH-exposed rats. ET-1 represents peak response to endothelin administration without MK-801, and MK-801 + ET-1 represents peak response to ET-1 after prior administration of the NMDA receptor blocker. **P < 0.01 vs. ET-1.